The application of CRISPR/Cas9 technology to HIV-1/AIDS treatment was first demonstrated in 2013 by Ebina et al. In their study, CRISPR/Cas9 was utilized to suppress HIV-1 gene expression in Jurkat cell lines by targeting two critical regions within the HIV-1 long terminal repeat: the NF-κB binding motifs in the U3 region and the TAR sequences within the R region [67]. This evidence concerns the gene NFKB1 and AIDS.